Patients with advanced hormone receptor-positive/HER2- negative/HER2-Enriched breast cancer research hub

A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA

This study compares two common breast cancer medicines, Kisqali and IBRANCE, for advanced hormone receptor-positive, HER2-negative or HER2-enriched breast cancer. It looks at how well they stop the cancer from growing and aims to see if one is better than the other.